Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5

Autor: Silver, P. J., Pagani, E. D., Dundore, R. L., Garavilla, L. De, Bode, D. C., Bacon, E. R.

Publikováno v: European Journal of Pharmacology; 1998, Vol. 349 Issue: 2 p263-268, 6p

Dissociation of antithrombotic and thrombocytopenic effects of D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone in rabbits

Autor: Dundore, R. L., Clas, D. M., VanAller, G. S., Habeeb, P. G.

Publikováno v: Thrombosis Research; 1994, Vol. 75 Issue: 6 p663-663, 1p

Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.

Autor: Dundore RL; Department of Vascular and Biochemical Pharmacology, Sterling Winthrop Pharmaceuticals Research Division, Collegeville, Pennsylvania 19426-0900., Pagani ED, Bode DC, Bacon ER, Singh B, Lesher GY, Buchholz RA, Silver PJ

Publikováno v: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 1995 Jan; Vol. 25 (1), pp. 14-21.

Hemodynamic and renal effects of the protein kinase inhibitor staurosporine in conscious rats.

Autor: Dundore RL; Department of Cardiovascular Pharmacology, Sterling Winthrop Pharmaceuticals Research Division, Rensselaer, New York 12144., Brousseau AC, Habeeb PG, Pratt PF, Becker LT, Clas DM, Silver PJ, Buchholz RA

Publikováno v: Journal of cardiovascular pharmacology [J Cardiovasc Pharmacol] 1992 Oct; Vol. 20 (4), pp. 525-32.

Comparative studies on cyclic nucleotide phosphodiesterases and inhibitors in experimental models of hypertension, congestive heart failure, and allergic asthma.

Autor: Silver PJ; Department of Cardiovascular Pharmacology, Sterling Research Group, Rensselaer, New York 12144., Gordon RJ, Buchholz RA, Dundore RL, Ferguson EW, Harris AL, Pagani ED

Publikováno v: Advances in second messenger and phosphoprotein research [Adv Second Messenger Phosphoprotein Res] 1992; Vol. 25, pp. 341-51.